Recipharm AB Update on Recipharm rights issue participation (6131U)
26 November 2019 - 6:01PM
UK Regulatory
TIDM0QSD TIDMCSRT
RNS Number : 6131U
Recipharm AB
26 November 2019
PRESS RELEASE 26 November 2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION.
THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN
INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES.
Larger institutional shareholders support Recipharm's cash offer
for Consort Medical and subsequent rights issue
Certain of Recipharm's larger institutional shareholders, Första
AP-fonden, Lannebo Fonder and Fjärde AP-fonden (holding 7.4%, 7.1%
and 5.1% of the total number of shares in Recipharm, respectively,
and together 19.6%), support the cash offer for Consort Medical and
have undertaken to fully support and vote in favour of a rights
issue at a forthcoming general meeting of Recipharm and have also
undertaken to subscribe for an amount corresponding to at least
their respective pro rata share in a rights issue of SEK 2,000
million.
As previously announced, Recipharm's largest shareholders,
Thomas Eldered and Lars Backsell (who together hold 27.1% of the
total number of shares in Recipharm), have already undertaken to
vote in favour of the rights issue at the forthcoming general
meeting of Recipharm and have also undertaken to subscribe for an
amount corresponding to their respective pro rata share in a rights
issue of SEK 2,000 million.
Thus, current shareholders in Recipharm, together holding 46.6%
of the total number of shares and 82.3% of the votes in Recipharm,
have undertaken to vote in favour of a rights issue at a
forthcoming general meeting of Recipharm and have also undertaken
to subscribe for their respective pro rata share in the rights
issue.
For more information please visit www.recipharm.com or
contact:
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Tobias Hägglöv, CFO, telephone: +46 8 602 45 00
This information is information that Recipharm AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency
of the contact persons set out above at 07:45 CET on 26 November,
2019.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing
Organisation (CDMO) in the pharmaceutical industry employing almost
7,000 employees. Recipharm offers manufacturing services of
pharmaceuticals in various dosage forms, production of clinical
trial material and APIs, and pharmaceutical product development.
Recipharm manufactures several hundred different products to
customers ranging from big pharma to smaller research and
development companies. Recipharm's turnover is approximately SEK
7.2 billion. The company operates development and manufacturing
facilities in France, Germany, India, Israel, Italy, Portugal,
Spain, Sweden, the UK and the US and is headquartered in Stockholm,
Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq
Stockholm.
For more information on Recipharm and our services, please visit
www.recipharm.com
IMPORTANT INFORMATION
This publication is neither an offer to buy or sell nor an
invitation to tender or offer to buy or sell shares.
This press release is not being published in or distributed to
or into and must not be mailed or otherwise distributed or sent in
or into any country in which the distribution or offering would
require any such additional measures to be taken or would be in
conflict with any law or regulation in such country. Persons who
receive this press release (including, without limitation,
nominees, trustees and custodians) and are subject to the law of
any such jurisdiction will need to inform themselves about, and
observe, any applicable restrictions or requirements. Any failure
to do so may constitute a violation of the securities laws of any
such jurisdiction.
To the extent this press release contains forward-looking
statements, such statements do not represent facts and are
characterized by the words "will", "expect", "believe", "estimate",
"intend", "aim", "assume" or similar expressions. Such statements
express the intentions, opinions or current expectations and
assumptions of Recipharm. Such forward-looking statements are based
on current plans, estimates and forecasts which Recipharm has made
to the best of its knowledge, but which do not claim to be correct
in the future. Forward-looking statements are subject to risks and
uncertainties that are difficult to predict and usually cannot be
influenced by Recipharm. It should be kept in mind that the actual
events or consequences may differ materially from those contained
in or expressed by such forward-looking statements.
Publication on a website
A copy of this announcement will be made available, subject to
certain restrictions relating to persons resident in restricted
jurisdictions, on Recipharm's website at
www.recipharm.com/investor-relations promptly and in any event by
no later than 12 noon (London time) on the business day following
this announcement. The content of the website referred to in this
announcement is not incorporated into and does not form part of
this announcement.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
OUPPGGUAGUPBPPA
(END) Dow Jones Newswires
November 26, 2019 02:01 ET (07:01 GMT)
Recipharm AB (LSE:0QSD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Recipharm AB (LSE:0QSD)
Historical Stock Chart
From Sep 2023 to Sep 2024